{
    "symbol": "IMAB",
    "quarter": 4,
    "year": 2022,
    "date": "2023-03-31 11:52:03",
    "content": " As a result, both parties are continuing to collaborate on the global development of anti-CD47 antibody therapy. As a result, both parties are continuing to collaborate on the global development of anti-CD47 antibody therapy. Secondly, the 4-1BB arm of givastomig is designed to function upon local tumor engagement as a mechanism of conditional activation. Secondly, the 4-1BB arm of givastomig is designed to function upon local tumor engagement as a mechanism of conditional activation. Our ongoing Phase 1 trial also gives us the initial confidence that, you know, we definitely have seen antitumor activity in Claudin18.2 low expression patients are granted."
}